Literature DB >> 14670225

Etiopathogenesis, classification, and current trends in treatment of rosacea.

Vesna Sredoja Tisma1, Aleksandra Basta-Juzbasić, Ivan Dobrić, Suzana Ljubojević, Zrinka Bukvić Mokos.   

Abstract

Rosacea is a common chronic dermatosis characterized by varying degrees of flushing, erythema, telangiectasia, edema, papules, pustules, ocular lesions, and phymas. Etiology and pathogenesis of rosacea are still unknown. Many possible causes have been described as inducing the disease or contributing to its manifestation, such as genetic predisposition, abnormal vascular reactivity, changes in vascular mediating mechanisms, Helicobacter pylori infection, Demodex folliculorum infestation, seborrhea, sunlight, hypertension, and psychogenic factors. However, none of these factors has been proved. Rosacea shows a wide spectrum of clinical presentations, which vary over time and with age. Successful management of rosacea requires careful patient evaluation and individualized therapy with appropriate variations and modifications, as the severity of the disorder fluctuates. In mild cases of rosacea, patients are instructed to avoid sun, to apply sun-protective creams, and to avoid facial irritants and other triggers that provoke symptoms. At later stage, drug therapy is often necessary. The disease commonly requires long-term treatment with topical or oral medicaments. Surgical correction may be required for rhinophyma and telangiectasia. We reviewed the current literature on the aspects of the pathogenesis, diagnostic criteria, and treatment options for rosacea.

Entities:  

Mesh:

Year:  2003        PMID: 14670225

Source DB:  PubMed          Journal:  Acta Dermatovenerol Croat        ISSN: 1330-027X            Impact factor:   1.256


  1 in total

1.  Role of Adenosine Deaminase in Patients with Erythematotelangiectatic Rosacea and Demodex folliculorum Positivity.

Authors:  Serpil Sener; Ulku Karaman; Tugba Raika Kiran; Cemil Colak; Ali Aslan; Sahin Direkel
Journal:  Iran J Parasitol       Date:  2020 Oct-Dec       Impact factor: 1.012

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.